TWI PHARMACEUTICALS HOLDING INC
TWi Pharmaceuticals, Inc. (TWi) is a technology-based special pharmaceutical company focusing on the development and commercialization of "Niche Generics" drugs with a regional focus on the US market. Unlike the common generic drugs, developing niche generic drugs require a full array of expertise, including advanced scientific research, process development, patent analysis, regulatory compliances, and market and competition analysis. TWi focuses on the development of the following two categories of niche generic drugs.
TWI PHARMACEUTICALS HOLDING INC
Social Links:
Industry:
Pharmaceutical
Founded:
2010-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.twipharma.com
Total Employee:
251+
Status:
Active
Contact:
+886-2-2657-3350
Email Addresses:
[email protected]
Technology used in webpage:
Euro SPF LetsEncrypt SSL By Default Microsoft Exchange Online Office 365 Mail Pound Sterling Microsoft Azure DNS ASP.NET IIS
Similar Organizations
China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company.
Taho Pharmaceuticals
Taihe Biotech Pharmaceutical Co., Ltd. (Taihe) is a biotechnology new drug development company
Theon Pharmaceuticals LTD.
Theon Pharmaceuticals is a pharmaceutical company.
Current Employees Featured
Founder
Official Site Inspections
http://www.twipharma.com Semrush global rank: 7.87 M Semrush visits lastest month: 682
- Host name: 60-250-122-32.hinet-ip.hinet.net
- IP address: 60.250.122.32
- Location: Taipei Taiwan
- Latitude: 25.0478
- Longitude: 121.5318
- Timezone: Asia/Taipei
More informations about "TWi Pharmaceuticals Holding Inc"
TWi Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TWi Pharmaceuticals, Inc. of Taipei City, Taipei. Get the latest business insights from Dun & …See details»
TWi Pharmaceuticals Holding Inc - Crunchbase
Contact Email [email protected] Phone Number +886-2-2657-3350 TWi Pharmaceuticals, Inc. (TWi) is a technology-based special pharmaceutical …See details»
TWi Pharmaceuticals Company Profile | Management and
Www.twipharma.com TWi Pharmaceuticals Profile and History TWi Pharmaceuticals USA Inc. is a wholly-owned subsidiary of TWi Pharmaceuticals Inc., a Taiwan-based specialty …See details»
TWi Pharmaceuticals, Taiwan - PharmaBoardroom
Feb 13, 2014 TWi Pharmaceuticals, Inc. headquartered in Taipei, Taiwan, is an emerging specialty pharmaceutical company focusing on the development, manufacturing and …See details»
TWi Pharmaceuticals, Inc. | LinkedIn
TWi Pharmaceuticals, Inc. | 1,844 followers on LinkedIn. focusing on the development and commercialization of "High Barrier to Entry" generic drugs. TWi focuses primarily on the …See details»
TWi Pharmaceuticals CEO and Key Executive Team | Craft.co
TWi Pharmaceuticals's President is Nick Liu. Other executives include Justin McManus, Vice President, Sales and Marketing; Janice Busam, Vice President of Finance and 2 others. See …See details»
Bora expands its CDMO capabilities as it makes landmark …
Sep 12, 2022 Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, has completed the acquisition of TWi Pharmaceutical Co.Ltd, a …See details»
TWi Pharmaceuticals
About TWi Pharmaceuticals, Inc. TWi Pharmaceuticals, Inc. (TWi) is a technology-based special pharmaceutical company focusing on the development and commercialization of "Niche …See details»
TWi Pharmaceuticals, Inc. Overview | SignalHire Company Profile
Focusing on the development and commercialization of "High Barrier to Entry" generic drugs. TWi focuses primarily on the development of Paragraph IV and high technical barrier generic drugs …See details»
TWi Pharmaceuticals USA, Inc. - Company Profile & Staff
Focusing on the development and commercialization of "High Barrier to Entry" generic drugs. TWi focuses primarily on the development of Paragraph IV and high technical barrier generic drugs …See details»
TWi Pharmaceuticals USA, Inc.
TWi focuses primarily on the development of Paragraph IV and high technical barrier generic drugs requiring strong science and technical know-how, as well as under-serviced mature …See details»
TWi Pharmaceuticals - Craft
TWi Pharmaceuticals (TWi) is a technology-based special pharmaceutical company focusing on niche generics drugs. It provides high barrier generic drugs with an expertise including …See details»
TWi Pharmaceuticals Announces That It Will Sell Its ... - Fierce …
Feb 24, 2015 TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products …See details»
TWi Pharmaceuticals USA, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TWi Pharmaceuticals USA, Inc. of Paramus, NJ. Get the latest business insights from Dun & …See details»
TWi Pharmaceuticals
Email：[email protected]; Business Development. If your are interested in discussing any business opportunities with us, please e-mail our Business Development team at …See details»
TWi Pharmaceuticals - Overview, News & Similar companies
Who is TWi Pharmaceuticals. TWi Pharmaceuticals USA Inc. is a wholly-owned subsidiary of TWi Pharmaceuticals Inc., a Taiwan-based specialty pharmaceutical company focusing on the …See details»
TWi Pharmaceuticals
As a Stand Alone Company Developing TWi's own generic and brand product for US market 2019. Obtained Dimethyl Fumarate DR Capsule tentative approval and Fenofibric Acid DR …See details»
TWi Pharmaceuticals
Mr. David Chou has more than 28 years of manufacturing and management experience for GMP pharmaceutical factory. Prior to joining TWi, David served for Center Laboratories, INC., …See details»
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a …
4 days ago Organization: PUB. Release Summary. Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCEâ„¢, a biosimilar to ACTEMRA®, …See details»
TWi PHARMACEUTICALS, INC. AND SUBSIDIARIES
Twi pharmaceuticals, inc. and subsidiaries consolidated statements of comprehensive income for the three months ended march 31, 2017 and 2018See details»